By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


AVEO Oncology (Formerly known as AVEO Pharmaceuticals, Inc.) 

75 Sidney Street, 4th Floor

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-299-5000 Fax: 617-995-4995


Key Statistics

Ownership: Public

Web Site: AVEO Oncology
Symbol: AVEO


Merck & Co.  Cancer

Company News
AVEO Oncology (AVEO) To Present At The 18th Annual BIO CEO & Investor Conference 2/2/2016 11:35:10 AM
AVEO Oncology (AVEO) To Present At Biotech Showcase 2016 1/6/2016 11:48:03 AM
AVEO Oncology (AVEO), EUSA Pharma Form $396.5 Million Exclusive Licensing Agreement for Tivozanib in Europe 12/21/2015 7:34:28 AM
AVEO Oncology (AVEO) Reports Third Quarter 2015 Financial Results And Provides Business Update 11/9/2015 11:46:17 AM
Retired Genzyme Chief Takes Over Board Leadership Responsibilities at AVEO Oncology (AVEO) 11/9/2015 6:30:59 AM
AVEO Oncology (AVEO) Forges $326 Million Antibody Pact With Novartis AG (NVS) 8/17/2015 5:36:47 AM
AVEO Oncology (AVEO) Reports Second Quarter 2015 Financial Results 8/10/2015 10:00:43 AM
AVEO Oncology (AVEO) To Host Midyear Update Conference Call On August 10, 2015 8/5/2015 11:49:37 AM
AVEO Oncology (AVEO) Announces Exclusive Licensing Agreement With Pharmstandard For Tivozanib In Russia, Ukraine And CIS 8/5/2015 11:01:19 AM
AVEO Oncology (AVEO) Announces Additional Biomarker Analyses From BATON-CRC Tivozanib Study To Be Presented At The ESMO 17th World Congress On Gastrointestinal Cancer 6/30/2015 11:24:05 AM